[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-444544-105":59,"doc-detail-444544-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","practical-brain-mri-guidelines-for-anti-a-antibody-treatment-in-early-symptomatic-alzheimers-disease","Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer’s Disease","","Guidelines to support MRI diagnosis for patients receiving anti-amyloid β (Aβ) antibody treatment in early symptomatic Alzheimer’s disease, aiming not to restrict treatment eligibility. Developed by Japanese professional societies through review of existing literature and clinical trial results. Facility standards should follow Japan’s Optimal Use Promotion Guidelines, with physicians trained in ARIA knowledge and brain MRI interpretation, including post-treatment diagnostic workflow and staffing for MRI management systems.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/practical-brain-mri-guidelines-for-anti-a-antibody-treatment-in-early-symptomatic-alzheimers-disease/444544/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/practical-brain-mri-guidelines-for-anti-a-antibody-treatment-in-early-symptomatic-alzheimers-disease/444544.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of these brain MRI guidelines?","Question",{"text":112,"@type":113},"They support accurate MRI diagnosis for patients receiving anti-amyloid β antibody treatment in early symptomatic Alzheimer’s disease, without limiting treatment eligibility.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the guidelines developed?",{"text":117,"@type":113},"They were collaboratively established by Japanese radiology-related societies by reviewing existing literature and clinical trial results.",{"name":119,"@type":110,"acceptedAnswer":120},"What key knowledge and facility standards are recommended?",{"text":121,"@type":113},"Facilities should meet Japan’s Optimal Use Promotion Guidelines, while physicians should be trained in ARIA knowledge and brain MRI interpretation, including post-treatment diagnosis and recommended staffing and MRI management systems.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},444544,1791097353,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Magn Reson Med Sci 2025 ; 24: 2025-1000  \n[doi:10.2463/mrms.gl.2025-1000 Published Online: April 5](doi:10.2463/mrms.gl.2025-1000 Published Online: April 5), 2025  \nGUIDELINE  \nPractical Brain MRI Guidelines for Anti-A β Antibody Treatment in Early Symptomatic Alzheimer’s Disease  \nShingo Kakeda1*, Yukio Miki2, Kohsuke Kudo3, Harushi Mori4,  \nAya M. Tokumaru5, Osamu Abe6, Shigeki Aoki7, Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, The Japanese Society for Neuroradiology, and The Japanese Society for Magnetic Resonance  \nin Medicine  \nPurpose: These guidelines aim to support MRI diagnosis in patients receiving anti-amyloid β (Aβ)  \nantibody treatment without restricting treatment eligibility.  \nMaterials and Methods: These guidelines were collaboratively established by Japan Radiological Society, The Japanese Society of Neuroradiology, and Japanese Society for Magnetic Resonance in Medicine by reviewing existing literature and the results of clinical trials.  \nResults: Facility standards should comply with the “Optimal Use Promotion Guidelines” of Japan, and physicians should possess comprehensive knowledge of amyloid-related imaging abnormalities (ARIA) and expertise in brain MRI interpretation. The acquisition of knowledge regarding amyloid-related imaging abnormalities, brain MRI, anti-Aβ antibody introduction, and post-treatment diagnosis are also recommended.  \nConclusion: These guidelines facilitate the accurate diagnosis and effective management of ARIA; ensure the safe administration of anti-Aβ drugs; and provide a framework for MRI facilities, includes staffing requirements and the use of MRI management systems.  \nKeywords: Alzheimer’s disease, amyloid-related imaging abnormalities, anti-amyloid beta antibody treatment, brain, guidelines, magnetic resonance imaging  \n1Department of Radiology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan  \n2Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan  \n3Department of Diagnostic Imaging, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan  \n4Department of Radiology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan  \n5Department of Diagnostic Radiology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan  \n6Department of Radiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan  \n7Department of Neurophysiology, Juntendo University School of Medicine, Tokyo, Japan  \n*Corresponding author: 1-1 Department of Radiology, Graduate School of Medicine, Hirosaki University, Hirosaki, Aomori 036-8562, Japan. Phone: +81-  \n172-39-5103, Fax: +81-172-33-5627, E-mail: [kakeda@hirosaki-u.ac.jp](kakeda@hirosaki-u.ac.jp)[ ](kakeda@hirosaki-u.ac.jp)This article has been jointly published in Japanese Journal of Radiology.  \nThis work is licensed under a Creative Commons Attribution 4 .0 International License.  \n©2025 Japanese Society for Magnetic Resonance in Medicine  \nIntroduction  \nFor the treatment of early Alzheimer ’s disease (AD), the Food and Drug Administration approved anti-amyloid β(Aβ) monoclonal antibodies: lecanemab (LeqembiTM) on July 6, 2023, and donanemab (Kisunla) on July 2, 2024 . In Japan, lecanemab was approved by the Japanese regulatory authorities on September 25, 2023, and was covered by the Japanese health insurance on December 20 .1 More recently, in Japan, medication coverage for donanemab became available on November 24, 2024 . Randomized clinical trials have shown that the use of anti-Aβ antibodies is associated with MRI signal abnormalities treatment-related adverse events called amyloid-related imaging abnormalities (ARIA) .2–11 Given that the presence of any hemorrhage on initial MRI (anti-Aβ antibody introduction MRI) increases the risk of ARIA, 12 the detection of cerebral microbleeds and superficial hemosiderosis","cbCaiohPHYf6pYkf","https://ap.wps.com/l/cbCaiohPHYf6pYkf","pdf",198849,"English","# Introduction\n# Purpose\n# Materials and Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What is the purpose of these brain MRI guidelines?\",\"answer\":\"They support accurate MRI diagnosis for patients receiving anti-amyloid β antibody treatment in early symptomatic Alzheimer’s disease, without limiting treatment eligibility.\"},{\"question\":\"How were the guidelines developed?\",\"answer\":\"They were collaboratively established by Japanese radiology-related societies by reviewing existing literature and clinical trial results.\"},{\"question\":\"What key knowledge and facility standards are recommended?\",\"answer\":\"Facilities should meet Japan’s Optimal Use Promotion Guidelines, while physicians should be trained in ARIA knowledge and brain MRI interpretation, including post-treatment diagnosis and recommended staffing and MRI management systems.\"}]","Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer’s Disease | PDF",1790708418]